28 Thus, the treatment effect of empagliflozin appears comparable to the treatment effect of ramipril versus placebo in the REIN study, which was terminated prematurely due to the highly significant benefit on eGFR decline. 28 Nevertheless, the statistically larger treatment benefit in the NRP group needs to be interpreted with caution and put in perspective with the fact that empagliflozin treatment completely abolished the annual eGFR decline in the non-NRP participants.
← all excerpts
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.
1
—
—